CENTERS FOR DISEASE CONTROL AND PREVENTION Patent applications |
Patent application number | Title | Published |
20140178868 | SELECTIVE DETECTION OF NEISSERIA MENINGITIDIS - A process for detecting | 06-26-2014 |
20140045174 | REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV-1 RESISTANCE TO ANTIVIRAL DRUGS - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein. | 02-13-2014 |
20140004139 | SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION | 01-02-2014 |
20130330726 | REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV-1 RESISTANCE TO ANTIVIRAL DRUGS - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase, protease, or integrase of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS: 1-89, 96-122, and 124-141. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS: 1-89, 96-122, and 124-141. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV simultaneously or sequentially. Mutations in the reverse transcriptase, protease, or integrase of HIV can be detected using the methods described herein. | 12-12-2013 |
20130321804 | ELECTRODE-ASSISTED MICROWAVE-INDUCED PLASMA SPECTROSCOPY - Particles of a flow of aerosol are collected and analyzed by passing them through a housing having an inlet area, an outlet area, and a collection and analysis area. A collection electrode has a tip disposed in the flow path in the collection and analysis area. Particles are collected on the tip of the collection electrode. A microwave pulse is applied to the collection and analysis area such that a plasma is created. Atomic emissions produced during at least part of the microwave step are collected for analysis of the ablated particles. | 12-05-2013 |
20130295557 | SELECTIVE DETECTION OF HAEMOPHILUS INFLUENZAE - A process for detecting | 11-07-2013 |
20130280714 | RAPID SALMONELLA SEROTYPING ASSAY - Processes for the serotype specific detection and identification of one or more | 10-24-2013 |
20130210031 | DETECTION OF ADENYLATE CYCLASE - One major problem in diagnosis methods presently available for anthrax is that these methods require several days to produce a result, are rendered unusable after antibiotic use, or are not quantifiable. The only existing treatment for anthrax requires administration soon after infection at a time when patients are exhibiting only mild flu-like symptoms. Thus, by the time a diagnosis is made a patient may be days beyond the time when treatment would be effective. The present invention reduces diagnosis time to as little as four hours providing same day identification of anthrax radically increasing the odds of delivering proper treatment and patient recovery. The rapid identification of anthrax edema factor activity exhibited by the invention is also amenable to in vivo screening protocols for the discovery and development of anthrax vaccines, anti-toxins and edema factor inhibitors. The invention isolates and concentrates edema factor and edema toxin from nearly any sample. By capitalizing on the adenylate cyclase activity of edema factor the invention amplifies output signals producing reliable detection of low concentrations of edema factor previously unachievable. The invention involves novel purification and detection techniques and substrates for rapid, reproducible, and quantitative measurements of anthrax edema factor, and other adenylate cyclases in biological samples. | 08-15-2013 |
20130095489 | PROCESS FOR DETECTION OF MULTIDRUG RESISTANT TUBERCULOSIS USING REAL-TIME PCR AND HIGH RESOLUTION MELT ANALYSIS - Compositions and process are provided for the rapid and specific detection of drug resistant forms of | 04-18-2013 |
20120329041 | REAL-TIME PCR POINT MUTATION ASSAYS FOR DETECTING HIV-1 RESISTANCE TO ANTIVIRAL DRUGS - Disclosed are compositions including primers and probes, which are capable of interacting with the disclosed nucleic acids, such as the nucleic acids encoding the reverse transcriptase or protease of HIV as disclosed herein. Thus, provided is an oligonucleotide comprising any one of the nucleotide sequences set for in SEQ ID NOS:1-89, and 96-104. Also provided are the oligonucleotides consisting of the nucleotides as set forth in SEQ ID NOS:1-89, and 96-104. Each of the disclosed oligonucleotides is a probe or a primer. Also provided are mixtures of primers and probes and for use in RT-PCR and primary PCR reactions disclosed herein. Provided are methods for the specific detection of several mutations in HIV. Mutations in both the reverse transcriptase and the protease of HIV can be detected using the methods described herein. | 12-27-2012 |
20120308597 | SEROLOGIC CORRELATES OF PROTECTION AGAINST BACILLIS ANTHRACIS INFECTION - Regions of | 12-06-2012 |
20120283135 | PRIMERS AND PROBES FOR DETECTION AND DISCRIMINATION OF TYPES AND SUBTYPES OF INFLUENZA VIRUSES - Methods of detecting influenza, including differentiating between type and subtype are disclosed, for example to detect, type, and/or subtype an influenza infection. A sample suspected of containing a nucleic acid of an influenza virus, is screened for the presence or absence of that nucleic acid. The presence of the influenza virus nucleic acid indicates the presence of influenza virus. Determining whether the influenza virus nucleic acid is present in the sample can be accomplished by detecting hybridization between an influenza specific probe, influenza type specific probe, and/or subtype specific probe and an influenza nucleic acid. Probes and primers for the detection, typing and/or subtyping of influenza virus are also disclosed. Kits and arrays that contain the disclosed probes and/or primers also are disclosed. | 11-08-2012 |
20120014981 | AVIRULENT, IMMUNOGENIC FLAVIVIRUS CHIMERAS - Chimeric flaviviruses that are avirulent and immunogenic are provided. The chimeric viruses are constructed to contain amino acid mutations in the nonstructural viral proteins of a flavivirus. Chimeric viruses containing the attenuation-mutated nonstructural genes of the virus are used as a backbone into which the structural genes of a second flavivirus strain are inserted. These chimeric viruses elicit pronounced immunogenicity yet lack the accompanying clinical symptoms of viral disease. The attenuated chimeric viruses are effective as immunogens or vaccines and may be combined in a pharmaceutical composition to confer simultaneous immunity against several strains of pathogenic flaviviruses. | 01-19-2012 |
20110270085 | ULTRASONIC IN SITU RESPIRATORY MASK TESTING PROCESS AND MASK - A respiratory mask includes a mask body with a perimeter. The mask has a use position wherein the mask body covers at least the mouth and nose and the perimeter is in contact with the face surrounding at least the mouth and nose. At least one ultrasonic sensor is supported on the mask body in detecting proximity to the perimeter. The ultrasonic sensor is operable to detect ultrasound. The ultrasonic sensor allows leakage around the perimeter of the mask body to be detected. | 11-03-2011 |
20110008360 | HUMAN ANTIBODIES AGAINST RABIES AND USES THEREOF - Human monoclonal antibodies that specifically bind to rabies virus, antigen binding portions thereof, and methods of making and using such antibodies and antigen binding portions thereof for treating rabies virus in a subject, are provided herein. | 01-13-2011 |
20100260802 | RECOMBINANT LIPIDATED PsaA PROTEIN, METHODS OF PREPARATION AND USE - The present invention relates to recombinant lipidated PsaA proteins and recombinant constructs from which such lipidated PsaA proteins may be expressed. The invention relates further to lipidated PsaA proteins in which lipidation is effected by the use of a heterologous leader sequence derived from the ospA gene of | 10-14-2010 |
20080292657 | PRIMATE T-LYMPHOTROPIC VIRUSES - Disclosed are compositions and methods related to the isolation and identification of the primate T-lymphotropic viruses, HTLV-3 and HTLV-4. The diversity of HTLVs was investigated among central Africans reporting contact with NHP blood and body fluids through hunting, butchering, and keeping primate pets. Herein it is shown that this population is infected with a variety of HTLVs, including two retroviruses; HTLV-4 is the first member of a novel phylogenetic lineage that is distinct from all known HTLVs and STLVs; HTLV-3 falls within the genetic diversity of STLV-3, a group that has not previously been seen in humans. The present disclosure also relates to vectors and vaccines for use in humans against infection and disease. The disclosure further relates to a variety of bioassays and kits for the detection and diagnosis of infection with and diseases caused by HTLV-3 and HTLV-4 and related viruses. | 11-27-2008 |